Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians

被引:0
作者
Fabiana B. Kohlrausch
Ángel Carracedo
Mara H. Hutz
机构
[1] Universidade Federal Fluminense (UFF),Departamento de Biologia Geral, Instituto de Biologia
[2] Universidade Federal do Rio Grande do Sul,Departamento de Genética
[3] CIBERER,Fundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica
来源
Molecular Biology Reports | 2014年 / 41卷
关键词
Polymorphisms; Variability; Pharmacogenetics; Cytochrome P450; Ethnicity; Brazil;
D O I
暂无
中图分类号
学科分类号
摘要
Potential causes of variability in drug response include intrinsic factors such as ethnicity and genetic differences in the expression of enzymes that metabolize drugs, such as those from Cytochrome P450 (CYPs) superfamily. Pharmacogenetic studies search for genetic differences between populations since relevant alleles occur with varying frequencies among different ethnic populations. The Brazilian population is one of the most heterogeneous in the world, resulting from multiethnic admixture of Amerindians, Europeans, and Africans across centuries. Since the knowledge of CYP allele frequency distributions is relevant to pharmacogenetic strategies and these data are scarce in the Brazilian population, this study aimed to describe genotype and allele distributions of 15 single nucleotide polymorphisms (SNPs) at CYP 1A2, 2C19, 3A4, and 3A5 genes in African and European descents from South Brazil. A sample of 179 healthy individuals of European and African ancestry was genotyped by the MassARRAY SNP genotyping system. CYP3A5*3, CYP1A2*1F, CYP3A4*1B, and CYP2C19*2 were the most frequent alleles found in our sample. Significant differences in genotype and allelic distribution between African and European descents were observed for CYP3A4 and CYP3A5 genes. CYP3A4*1B was observed in higher frequency in African descents (0.379) than in European descents (0.098), and European descents showed higher frequency of CYP3A5*3 (0.810) than African descents (0.523). Our results indicate that only a few polymorphisms would have impact in pharmacogenetic testing in South Brazilians. Further studies with larger sample sizes are required also among other Brazilian regions.
引用
收藏
页码:1453 / 1460
页数:7
相关论文
共 567 条
[1]  
Nebert DW(2006)Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics Trends Pharmacol Sci 27 580-586
[2]  
Vesell ES(2005)Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy Philos Trans R Soc Lond B Biol Sci 360 1563-1570
[3]  
Ingelman-Sundberg M(2007)The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects Am Fam Physician 76 391-396
[4]  
Rodriguez-Antona C(2004)Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 442-473
[5]  
Lynch T(1994)Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 414-423
[6]  
Price A(2002)Common allelic variants of cytochrome P4503A4 and their prevalence in different populations Pharmacogenetics 12 121-132
[7]  
Kirchheiner J(2007)Individualized drug therapy Curr Opin Drug Discov Dev 10 29-36
[8]  
Nickchen K(2000)CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity Clin Pharmacol Ther 67 48-56
[9]  
Bauer M(2005)CYP3A4 and CYP3A5 genotyping by Pyrosequencing BMC Med Genet 6 19-1069
[10]  
Wong ML(2004)CYP3A variation and the evolution of salt-sensitivity variants Am J Hum Genet 75 1059-391